ImmunoGen Inc. (IMGN) Trading Up 0%
ImmunoGen Inc. (NASDAQ:IMGN) shares were up 0% during trading on Tuesday . The company traded as high as $2.80 and last traded at $2.69, with a volume of 890,431 shares trading hands. The stock had previously closed at $2.69.
A number of research analysts have recently commented on IMGN shares. Jefferies Group reissued a “buy” rating and set a $6.00 price target (down from $13.00) on shares of ImmunoGen in a report on Friday, August 5th. Zacks Investment Research raised ImmunoGen from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Cantor Fitzgerald reissued a “hold” rating on shares of ImmunoGen in a report on Wednesday, June 8th. JPMorgan Chase & Co. set a $5.00 price target on ImmunoGen and gave the company a “hold” rating in a report on Friday, August 5th. Finally, Cowen and Company reissued a “hold” rating on shares of ImmunoGen in a report on Monday, June 6th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $11.72.
The company’s market capitalization is $241.35 million. The firm’s 50-day moving average price is $2.93 and its 200-day moving average price is $5.36.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/immunogen-inc-imgn-trading-up-0.html
ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.51) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.12. The company earned $7.41 million during the quarter, compared to analyst estimates of $17.11 million. ImmunoGen had a negative net margin of 239.42% and a negative return on equity of 530.98%. ImmunoGen’s quarterly revenue was down 41.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.35) EPS. Equities research analysts expect that ImmunoGen Inc. will post ($1.61) earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. Wade G W & Inc. acquired a new position in shares of ImmunoGen during the second quarter valued at about $102,000. Northeast Financial Consultants Inc increased its position in shares of ImmunoGen by 102.0% in the second quarter. Northeast Financial Consultants Inc now owns 34,315 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 17,330 shares during the last quarter. Wrapmanager Inc. increased its position in shares of ImmunoGen by 9.4% in the first quarter. Wrapmanager Inc. now owns 15,877 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 1,368 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of ImmunoGen by 3.6% in the second quarter. Nationwide Fund Advisors now owns 57,383 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 1,999 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of ImmunoGen during the second quarter valued at about $177,000. Hedge funds and other institutional investors own 91.63% of the company’s stock.
ImmunoGen, Inc (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company’s clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells.
Receive News & Ratings for ImmunoGen Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ImmunoGen Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.